{
    "clinical_study": {
        "@rank": "154654", 
        "arm_group": [
            {
                "arm_group_label": "Clopidogrel napadisilate", 
                "arm_group_type": "Experimental", 
                "description": "aspirin 100mg"
            }, 
            {
                "arm_group_label": "clopidogrel bisulfate", 
                "arm_group_type": "Active Comparator", 
                "description": "aspirin 100mg"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to demonstrate that the combination therapy of aspirin and\n      clopidogrel napadisilate is not inferior to that of aspirin and clopidogrel bisulfate with\n      respect to its effectiveness in inhibiting platelet aggregation, if it is given for four\n      weeks to Coronary Artery Disease (CAD) patients who had been treated with a drug-eluting\n      stent before > 12 months and had remained in a stable condition with a single antiplatelet\n      agent, aspirin."
        }, 
        "brief_title": "Comparison of Effect & Safety of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients", 
        "completion_date": {
            "#text": "December 2009", 
            "@type": "Actual"
        }, 
        "condition": "Coronary Artery Disease (CAD)", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  aged 20 to 80 years\n\n          -  men and women with coronary artery disease who had been treated with drug-eluting\n             stent placement before > 12 months\n\n          -  patients who had remained in a stable condition with a single antiplatelet agent,\n             aspirin\n\n          -  patients who did not show any sign or symptom of the worsening of their angina within\n             the last six months that required a coronary artery intervention, a coronary artery\n             bypass, or coronary angiography\n\n        Exclusion Criteria:\n\n          -  Patients who were taking another antiplatelet or anticoagulant drug such as\n             clopidogrel, warfarin, or cilostazol in addition to aspirin, unless they could\n             withdraw from such other drug/s, in which case they could be enrolled in the study\n             after a two-week wash-out period\n\n          -  Patients who were suffering from drug abuse or alcohol addiction\n\n          -  hypersensitivity to clopidogrel or aspirin\n\n          -  severe liver disease (ALT or AST \u2265 10 times the upper normal limit)\n\n          -  active hemorrhage such as gastro-intestinal ulcer or intracranial hemorrhage\n\n          -  a high risk of bleeding (blood coagulation disorder, uncontrolled severe\n             hypertension, active bleeding, or history of severe bleeding)\n\n          -  pregnant or lactating women\n\n          -  women with childbearing potential who were not using an appropriate contraception\n             method\n\n          -  had medical or mental contra-indications to the study treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "162", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01830491", 
            "org_study_id": "HM-CPG-401"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Clopidogrel napadisilate", 
                    "clopidogrel bisulfate"
                ], 
                "intervention_name": "Clopidogrel", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Pidogul\u00ae", 
                    "Plavix\u00ae"
                ]
            }, 
            {
                "arm_group_label": [
                    "Clopidogrel napadisilate", 
                    "clopidogrel bisulfate"
                ], 
                "intervention_name": "aspirin 100mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Aspirin", 
                "Ticlopidine", 
                "Clopidogrel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 9, 2013", 
        "number_of_arms": "2", 
        "official_title": "Comparison of Antiplatelet Effect and Safety of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients: Multi-center, Randomized, Double-blind, Phase IV Clinical Trial", 
        "overall_official": {
            "affiliation": "Seoul National University Hospital", 
            "last_name": "Byung-Hee Oh, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "the percent inhibition of the platelet aggregation change", 
            "safety_issue": "No", 
            "time_frame": "baseline and 4weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01830491"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "the change of P2Y12 reaction unit (PRU)", 
            "safety_issue": "No", 
            "time_frame": "baseline and 4weeks"
        }, 
        "source": "Hanmi Pharmaceutical Company Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hanmi Pharmaceutical Company Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}